検索新着情報News
【TargetMol】新製品(1月版)のご紹介
- 2025/02/17
- サプライヤニュース
 |
|
| New Compound | January |
 |
RIPK2-IN-3 (FCG806791773) is a receptor-interacting serine/threonine protein kinase 2 (RIPK2) inhibitor with anti-inflammatory and anti-tumor activity. It can be used for research on immune diseases and cancer.
Research Areas: Cancer Targets: RIP kinase |
|
MK-3984 is a selective androgen receptor modulator, used in the study of conditions caused by androgen deficiency.
Research Areas: Cancer Targets: Androgen Receptor |
 |
 |
DT204 is an SCFSkp2 inhibitor that reduces the binding of Skp2 to Cullin-1 and Commd1. It can be used to study multiple myeloma.
|
|
BMH-7 HCl is a p53 activator, showing anticancer activity through the activation of the p53 pathway.
Research Areas: Others Targets: Others |
 |
 |
Factor B-IN-5 is a complement factor B inhibitor, which can be used to study immune-related diseases.
Research Areas: Inflammation/Immunology Targets: Complement System |
|
PF-06647263 (anti-EFNA4-ADC) is an ADC compound targeting EFNA4, with anti-tumor activity, composed of an anti-EFNA4 antibody conjugated with calicheamicin, inducing significant tumor regression in TNBC xenografts.
Research Areas: Cancer Targets: Antibody-Drug Conjugates (ADCs); DNA Alkylator/CrosslinkerAntibioticApoptosis |
 |
 |
RMM-46 is a reversible covalent inhibitor with high ligand efficiency and selectivity for MSK/RSK family kinases.
Research Areas: Cancere Targets: MAPKAPK2 (MK2) |
|
|
* {
font-family: Verdana, Alright Sans, Calibri, Arial, Helvetica, Sans-Serif;
}
.compound_name {
font-weight: bold;
font-size: 17px;
padding: 0px 0px 2px 2px;
text-align: left
}
.compound_des {
font-size: 12px;
padding: 3px 0px 3px 0px;
}
.compound_img {
border-style: none;
padding: 2px 2px 2px 2px;
}
.learn_more {
padding: 0px 0px 2px 2px;
font-size: 14px;
font-weight: bold;
color: #D8D8E1;
text-align: right
}
a:link {
color: #4852A9;
}
a:visited {
color: #4852A9;
;
}
a:hover {
color: #4852A9
;
8;
}
a:active {
color: lightgrey
}
.menu {
background: #FFF0FC;
font-size: 13px;
font-weight: bold;
text-align: center;
padding: 20px 20px 20px 20px;
}
.blank_row {
background-color: #D8D8E1
}
.nav_item{
padding: 10px;
display: flex;
justify-content: center;
}
.nav_item> a {
width: 25%;
text-align: center;
}
/* CMS Other Editor Test */
@media only screen and (max-width: 480px){
body { margin: 0; padding: 0; }
}
@media only screen and (max-width: 480px){
table[class=container-table], .bmeheadertext, .container-table{ width: 95% !important;}
}
@media only screen and (max-width: 480px){
.header{font-size: 24px !important;}
}
@media only screen and (max-width: 480px){
.contenttitle{font-size: 20px !important;line-height: 140% !important;}
}
@media only screen and (max-width: 480px){
.contenttext{font-size: 16px !important;line-height: 140% !important;}
}
@media only screen and (max-width: 480px){
.single-col{display: block !important; width: 100% !important; float:left; clear:both;}
}
@media only screen and (max-width: 480px){
img.mobile-img-large { width: 100% !important; height:auto !important;display:block;}
}
@media only screen and (max-width: 480px){
img.bmeRSSImage{max-width:300px; height:auto !important;}
}
@media only screen and (max-width: 480px){
td[class="preheader-table"]{padding: 10px 0 !important;}
}
@media only screen and (max-width: 480px){
div[class="bmeheadertext"]{font-size: 12px !important;line-height: 140% !important;}
}
@media only screen and (max-width: 480px){
td[class="bmefootertext"], div[class="bmefootertext"]{font-size: 12px !important;padding-top: 10px;line-height: 140% !important;}
}
@media only screen and (max-width: 480px){
div[class="bmefooter"] td[width="79%"], div[class="bmefooter"] td[width="21%"]{display: block !important;width: 100%;}
}
@media only screen and (max-width: 480px){
.mobile-footer, .mobile-footer a{ font-size: 13px !important; line-height: 18px !important;}
}
@media only screen and (max-width: 480px){
.mobile-footer{ text-align: center !important;}
}
@media only screen and (max-width: 480px){
div.bmefooter, div.bmeheader{ display:block !important;}
}
@media only screen and (max-width: 480px){
table[class="share-tbl"] { padding-bottom: 15px; width: 100% !important;}
}
@media only screen and (max-width: 480px){
table[class="share-tbl"] td { display: block !important; text-align: center !important; width: 100% !important;}
}
@media only screen and (min-width: 640px){
img.bmeRSSImage{max-width:500px !important; height:auto !important;}
}
/* ---extra-- */
table[width="100%"] { width: 100%; }
table[align="center"] { margin: 0 auto; }
td[align="center"] { text-align: center; }
table[width="640"] { width: 640px; }
.compound_des{ line-height: 1.2; }
main#stargetmol section table tbody tr td { text-align: left; }
td[align="right"] { text-align: right !important; }
TargetMol(ターゲットモル)社について
- 本社所在地
- アメリカ マサチューセッツ州
- URL
- https://www.targetmol.com/
TargetMolは、ボストンに本社を置く低分子およびスクリーニングライブラリのサプライヤです。ライフサイエンス試薬、阻害剤、活性剤、実験用および科学用の天然化合物を提供しています。ポートフォリオには、6,000を超える化合物/阻害剤（カタログ）と80種類を超える化合物ライブラリがあります。